Jim Cramer is bullish on Wingstop, Sanofi, Micron Technology and Nisource.
The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.
Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.
There's a forest fire in the sector.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.